Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:MESO 3 October 2025 - 12 January 2026

Mesoblast Stock Jumps on Ryoncil Milestone – Analysts See 40% Upside

Mesoblast Stock Jumps on Ryoncil Milestone – Analysts See 40% Upside

Mesoblast shares closed at $17.02 on Oct. 2, up 4.6% after the FDA-approved Ryoncil won permanent CMS reimbursement via a new J-code. The company confirmed its cell therapies are made from U.S. donors and not subject to tariffs. Wall Street consensus is “Buy” with a $24 average price target. Hedge funds have increased stakes, but overall institutional ownership remains low.
3 October 2025
··

Stock Market Today

  • Evertz Technologies Fair Value Targets Lifted by Analysts on TSX
    March 20, 2026, 2:37 PM EDT. Analysts have raised the fair value estimate for Evertz Technologies (TSX:ET) from CA$14.88 to CA$17.25, reflecting a roughly 16% increase and aligning with a cluster of price targets between CA$16 and CA$17.50. Canaccord and BMO Capital have each lifted their price targets to CA$17.50, maintaining positive ratings, while RBC Capital has raised its target incrementally to CA$16 but retains a cautious Sector Perform stance. The upward revisions follow updated assumptions, including a slight dip in revenue growth to 4.16% and an improved net profit margin to 12.98%. The stock's quarterly dividend was declared at CA$0.2050 per share, payable March 2026. Investors should note the narrowed upside range and potential risks flagged, advising careful consideration of entry points and expectations.
Go toTop